About Dataset
Similar Datasets
- Hepatitis C Dataset: LINK
- Body Fat Prediction Dataset: LINK
- Cirrhosis Prediction Dataset: LINK
- Stroke Prediction Dataset: LINK
- Stellar Classification Dataset - SDSS17: LINK
- Wind Speed Prediction Dataset: LINK
- Spanish Wine Quality Dataset: LINK
- Electric Power Consumption: LINK
Context
Since the start of the COVID-19 pandemic there have been over 290 million confirmed infections and 5 million deaths reported worldwide. Because of the unprecedented burden on healthcare resources, many healthcare activities such as chronic disease management, cancer screening and cancer treatments have been cancelled or delayed. Consequently, referrals of suspected new cancers have reduced, with increases in cancer-related deaths predicted.
The full impact of the COVID-19 pandemic on patients with primary liver cancer (PLC) has yet to be determined, although European data reported a disruption to hepatocellular carcinoma (HCC) services, a reduction in incident cases and an impact on management during the first wave of the pandemic (February 2020 to May 2020).
The data was prospectively collected on all patients referred to the Newcastle-upon-Tyne NHS Foundation Trust (NUTH) hepatopancreatobiliary multidisciplinary team (HPB MDT) in the first 12 months of the pandemic (March 2020-February 2021), comparing to a retrospective observational cohort of consecutive patients presenting in the 12 months immediately preceding it (March 2019-February 2020). All new cases with a diagnosis of hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) confirmed radiologically or histologically, following international guidelines, were included.
The objective is to assess the impact of the COVID-19 pandemic on patients with newly diagnosed liver cancer.
Attribute Information
- Cancer: Cancer flag [Y/N]
- Year: Categorical [Prepandemic (March 2019–February 2020)/Postpandemic(March 2020–February 2021)]
- Month: Month of the year 1-12
- Bleed: Spontaneous tumour haemorrhage [Y/N]
- Mode Presentation: Surveillance, Incidental, or Symptomatic
- Age: Age of the patitent
- Gender: Male or Female [M/F]
- Etiology: manner of causation of a disease or condition. Either "No established CLD" (chronic liver disease), "ARLD" (alcohol-related liver disease), "NAFLD" (non-alcoholic fatty liver disease), "HCV" (hepatitis C virus), "HH" (hereditary haemochromatosis), "PBC/AIH" (primary biliary cholangitis/autoimmune hepatitis), "HBV" (hepatitis B virus), or "Other".
- Cirrhosis: Underlying liver disease [Y/N]
- Size: Tumour diameter in mm
- HCC TNM Stage: Hepatocellular carcinoma Tumour node metastasis Stage ("I", "II", "IIIA+IIIB", "IV")
- HCC BCLC Stage: Hepatocellular carcinoma Barcelona Clinic for Liver Cancer Stage ("0", "A", "B", "C", "D")
- ICC TNM Stage: Intrahepatic cholangiocarcinoma Tumour node metastasis Stage ("I", "II", "III", "IV")
- Treatment grps: First-line treatment received ["OLTx" (orthotopic liver transplantation), "Resection", "Ablation", "TACE"" (transarterial chemoembolisation), "SIRT" (selective internal radiation therapy), "Medical", "Supportive care"]
- Survival from MDM: Survival from Multidisciplinary meeting
- Alive Dead: "Alive", "Dead"
- Type of incidental finding: ("Primary care-routine", "Secondary care-routine", "Primary care-acute", "Secondary care-acute")
- Surveillance programme: Patient in a formal surveillance programme ("Y", "N")
- Surveillance effectiveness: Surveillance adherence over previous year ("Consistent", "Inconsistent", "Missed")
- Mode of surveillance detection: Mode of incident surveillance test ["US" (ultrasound), "AFP alone" (alpha-fetoprotein alone), "CT/MRI"]
- Time diagnosis 1st Tx:
- Date incident surveillance scan: ("Y", "N")
- PS: Performance status [0, 1, 2, 3, 4]
- Time MDM 1st treatment: Time to Multidisciplinary meeting 1st treatment
- Time decision to treat 1st treatment: Time decision to treat 1st treatment
- Prev known cirrhosis: ["Y", "N"]
- Months from last surveillance: Months from last surveillance
Citation
fedesoriano. (September 2022). COVID-19 effect on Liver Cancer Prediction Dataset. Retrieved [Date Retrieved] from https://www.kaggle.com/datasets/fedesoriano/covid19-effect-on-liver-cancer-prediction-dataset.
Acknowledgements
Author: Helen Reeves
Contact: helen.reeves@newcastle.ac.uk
Last updated: 13.04.2022
DOI: http://dx.doi.org/10.1136/bmjgast-2021-000794